Medical Studies & Research

Key Finding: Participants taking the highest dose (12 mg) lost an average of 24.2% of their body weight over 48 weeks — more than any other weight-loss drug studied to date. 100% of participants on the 8 mg and 12 mg doses lost at least 5% of their body weight. 72% of those with prediabetes at baseline returned to normal blood sugar levels.

Key Finding: Retatrutide reduced HbA1c (a key blood sugar marker) by 2.2 percentage points and led to 16.9% average weight loss — far outperforming both placebo and dulaglutide. 82% of participants achieved healthy blood sugar levels (HbA1c ≤ 6.5%).

Key Finding: Retatrutide reduced liver fat by up to 82.4% in the highest dose group. More than 90% of participants with fatty liver disease achieved normalization of liver fat content — a result researchers described as unprecedented.

Key Finding: BPC-157 consistently improved healing outcomes in muscle, tendon, ligament, and bone injury models. It works by boosting growth factors, promoting blood vessel formation, and reducing inflammation. In a human clinical observation, 7 out of 12 patients with chronic knee pain reported relief for over 6 months after a single BPC-157 knee injection. No toxic dose was identified across a wide dosing range.

Key Finding: BPC-157 significantly accelerated the outgrowth of tendon tissue and increased cell migration in a dose-dependent manner. It activated the FAK-paxillin signaling pathway — a key mechanism for cell movement and attachment during healing.

Key Finding: BPC-157 promotes healing through at least four separate biological mechanisms simultaneously — making it uniquely effective for poorly vascularized tissues like tendons. No toxic or lethal dose was ever established. Its favorable safety profile has led researchers to call for formal human clinical trials.

Key Finding: Clinical trials showed GHK-Cu facial cream significantly improved skin laxity, reduced wrinkles, and increased skin density in 71 women over 12 weeks. Skin biopsy studies found it increased collagen production in 70% of participants — outperforming both Vitamin C cream and retinoic acid. It also regulates 31% of the human genome and may reverse age-related changes in gene expression.

Key Finding: GHK-Cu significantly decreased reactive oxygen species (ROS) in cells, reduced TNF-α and IL-6 inflammatory markers, and preliminary mouse studies showed improved learning in aged animals treated for 3 weeks. Researchers proposed GHK-Cu as a candidate therapy against age-associated neurodegeneration.

Key Finding: Human studies confirm NAD+ precursors can safely raise blood NAD+ levels. Early clinical trials report benefits including reduced blood pressure, improved lipid profiles in overweight older adults, prevention of kidney injury, and suppression of inflammation in Parkinson's disease. Researchers called for larger randomized trials to confirm efficacy across age-related conditions.

Key Finding: All NMN doses significantly raised blood NAD+ levels compared to placebo in a dose-dependent pattern. The compound was safe and well-tolerated with no serious adverse events. Higher doses produced greater NAD+ increases, with 900 mg showing the most significant elevation.

Key Finding: Semax produced EEG changes consistent with known neuroprotective drugs, and demonstrated measurable nootropic activity in human participants. The study established Semax as the first domestic neuropeptide-based nootropic with documented effects in both lab models and humans.

Key Finding: A single dose of Semax produced a 1.4-fold increase in BDNF protein levels and a 3-fold increase in BDNF gene expression in the hippocampus. Animals treated with Semax showed significantly improved performance on learning and memory tasks, suggesting Semax enhances cognitive function by activating the brain's own growth factor system.

Key Finding: Semax-treated mice showed significant improvement in cognitive function across all three behavioral tests. Crucially, the number of amyloid plaques in the brain was reduced by 2.6-fold in the Semax group compared to untreated Alzheimer's model mice — a dramatic reduction in the hallmark pathology of the disease.

Key Finding: Participants on semaglutide lost an average of 14.9% of their body weight — nearly triple the 2.4% seen in the placebo group. 86.4% of semaglutide participants achieved at least 5% weight loss. Blood pressure, blood sugar, and cholesterol all improved significantly.

Key Finding: Tesamorelin reduced visceral adipose tissue by approximately 15-18% compared to placebo over 26 weeks. It also improved triglyceride levels and quality of life measures. The FDA subsequently approved Tesamorelin for clinical use — one of the few peptides to achieve full FDA approval.

Key Finding: Multiple clinical trials and meta-analyses confirm Thymosin Alpha-1 significantly improves immune response in immunocompromised patients. Studies in COVID-19 patients showed dramatically reduced mortality and ICU admission rates. Its strong safety profile and immunomodulatory properties have made it one of the most clinically studied immune peptides globally.

Key Finding: Epitalon restored melatonin levels in elderly patients, improved immune function, and regulated cortisol and gonadotropin levels. Long-term follow-up studies showed reduced incidence of cardiovascular disease, respiratory illness, and cancer in treated elderly cohorts. Researchers noted Epitalon activates telomerase — the enzyme that repairs and lengthens telomeres, the structures that protect chromosomes from aging.

Key Finding: Selank produced significant reductions in anxiety scores without the sedation, tolerance, or dependence associated with benzodiazepines. It also improved cognitive function and memory in anxious patients — an effect benzodiazepines do not provide. Selank modulates BDNF expression and serotonin/dopamine balance, explaining its dual anxiolytic-nootropic profile.

Key Finding: AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) in animal models at rates comparable to human growth hormone — but without affecting blood sugar or IGF-1 levels. Phase 2 clinical trials in obese adults showed significant fat loss without metabolic side effects. The FDA granted it GRAS (Generally Recognized as Safe) status.

Key Finding: PT-141 significantly increased the number of satisfying sexual events and reduced distress associated with low sexual desire compared to placebo. 25% of women reported a clinically meaningful improvement in desire versus 17% on placebo. It is the only FDA-approved centrally-acting sexual desire medication — operating through melanocortin pathways in the brain, not vascular pathways.

Key Finding: Thymosin Beta-4 increased re-epithelialization (skin regrowth) by 42% at 4 days and up to 61% at 7 days compared to untreated controls. It also significantly increased collagen deposition and new blood vessel formation. Cell migration in lab assays was stimulated 2-3 fold with as little as 10 picograms of the peptide — making it one of the most potent wound-healing signals ever identified.

Key Finding: In two Phase 2 clinical trials of chronic non-healing wounds (stasis ulcers and pressure ulcers), Thymosin Beta-4 accelerated healing by almost a full month in patients who did heal. The peptide works through multiple pathways simultaneously: it promotes cell migration, mobilizes stem cells, inhibits inflammation, prevents programmed cell death (apoptosis), and reduces scar formation by decreasing myofibroblast density.

Key Finding: Tβ4 promoted angiogenesis, accelerated wound repair, and stimulated hair follicle development in both normal and aged animals — showing no age-related decline in efficacy. This makes it particularly relevant for aging research. At the time of publication the peptide was already in clinical trials for wound repair.

Key Finding: FOXO4-DRI selectively triggered apoptosis (programmed cell death) in senescent cells while leaving healthy cells completely unharmed. In naturally aged mice and chemotherapy-treated mice (both models with high senescent cell loads), FOXO4-DRI restored fur density, improved liver and kidney function, increased exploratory behavior, and significantly boosted voluntary physical activity. Animals were treated for over 10 months with no observed side effects.

Key Finding: FOXO4-DRI selectively induced apoptosis in senescent Leydig cells, improved the testicular microenvironment, and significantly increased testosterone synthesis in naturally aged mice. The treatment restored the hormonal production capacity of the tissue by clearing the cells that were blocking normal function — without harming healthy Leydig cells.

Key Finding: FOXO4-DRI injection in both naturally aged mice and chemically-induced aging models suppressed aortic aging and significantly improved aortic function. It selectively eliminated senescent endothelial cells, reduced vascular inflammation, and improved endothelium-dependent vasodilation — the key measure of a blood vessel's ability to relax and expand properly.

Key Finding: ARA-290 produced significant reductions in pain scores and neuropathic symptoms compared to placebo. Quality of life, fatigue, and depression scores all improved. The most striking finding was that ARA-290 increased the density of corneal nerve fibers — direct physical evidence of nerve regeneration and repair. No safety concerns were raised. ARA-290 was later granted FDA Orphan Drug status for neuropathic pain in sarcoidosis.

Key Finding: ARA-290 improved HbA1c (blood sugar control) and lipid profiles throughout the 56-day observation period. Neuropathic pain scores improved significantly compared to placebo. Importantly, benefits persisted even after the 28-day treatment ended — suggesting a disease-modifying rather than merely symptomatic effect. No safety concerns were identified across the entire trial.

Key Finding: GlyNAC supplementation corrected glutathione deficiency and reversed multiple hallmarks of aging simultaneously in older adults — including oxidative stress, mitochondrial dysfunction, insulin resistance, inflammation, endothelial dysfunction, muscle strength decline, and cognitive impairment. These improvements were not seen in the placebo group. The researchers described this as the first placebo-controlled trial to successfully reverse multiple age-related defects at once.

Key Finding: GSH levels decline consistently with age in both blood and brain regions (particularly the precuneus, cingulate cortex, and occipital regions). A lower GSH:GSSG ratio — meaning more oxidized, less functional glutathione — is observed reliably in older adults compared to younger controls. The researchers identified 25 active clinical trials using glutathione supplementation as a treatment or outcome measure, reflecting the scientific community's growing interest in GSH restoration as an anti-aging strategy.

Key Finding: MOTS-C treatment prevented both age-dependent insulin resistance and high-fat-diet-induced obesity in mice. It works primarily through the AMPK pathway — the same pathway activated by exercise and caloric restriction. Critically, MOTS-C levels in human blood decline with aging (young adults have 21% higher levels than elderly), suggesting it may be one of the molecular reasons metabolism slows down as we age.

Key Finding: MOTS-C significantly enhanced physical performance in mice of ALL age groups — young, middle-aged, and old — improving grip strength, gait, and aerobic capacity. Late-life treatment (started at age 23.5 months, equivalent to ~70+ human years) still increased physical capacity and healthspan. In humans, exercise directly induces MOTS-C expression in skeletal muscle and circulation — establishing it as a natural exercise-responsive hormone.

Key Finding: MOTS-C has now been shown to have beneficial effects on diabetes (improving insulin sensitivity), cardiovascular disease (reducing inflammation), osteoporosis (improving bone density), and Alzheimer's disease (reducing amyloid pathology in models). Plasma MOTS-C levels naturally decline with age across both humans and mice, and this decline correlates with the deterioration of multiple metabolic functions. The authors propose MOTS-C as a hormone-like regulator of healthy aging.

Key Finding: A single injection of CJC-1295 increased mean plasma growth hormone levels by 2 to 10-fold for 6 days or more, and IGF-I levels by 1.5 to 3-fold for 9–11 days. After multiple doses, IGF-I remained elevated for up to 28 days. No serious adverse reactions were reported. The authors concluded these data "support the potential utility of CJC-1295 as a therapeutic agent."

Key Finding: Ipamorelin released GH with high potency comparable to GHRP-6, but even at doses 200 times higher than the effective GH-releasing dose, ipamorelin did not raise ACTH or cortisol — a profile unique among GH secretagogues at the time of publication. This selectivity makes it ideal for combination with CJC-1295, as the two work through complementary mechanisms: CJC-1295 raises the GH baseline over days, while Ipamorelin triggers clean pulsatile GH release.

Key Finding: In vitro studies showed SNAP-8 reduced neuromuscular junction activity by modulating SNARE complex formation. Clinical cosmetic studies demonstrated measurable reductions in wrinkle depth and expression line severity with regular topical application. It is particularly effective for crow's feet, forehead lines, and perioral wrinkles. As a research compound, it is studied for its potential in non-invasive modulation of neuromuscular signaling.

Key Finding: Research shows DSIP promotes slow-wave (delta) sleep without suppressing REM sleep, modulates the stress response by reducing plasma ACTH and cortisol, normalizes disrupted sleep cycles, and possesses antioxidant and neuro-protective properties. Clinical studies in humans reported improvements in insomnia, chronic pain, and withdrawal symptoms. Unlike benzodiazepines and other sleep medications, DSIP does not appear to cause dependence or rebound insomnia.